Trial Profile
Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-Ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine
- Indications Rectal cancer
- Focus Biomarker; Therapeutic Use
- 27 Jun 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 27 Jun 2012 Planned End Date 1 Dec 2013 added as reported by ClinicalTrials.gov.
- 25 Jun 2011 Results presented at the 13th World Congress on Gastrointestinal Cancer.